Abstract
e16189Background: S-1, an oral fluoropyrimidine, combined with Irinotecan (IRI) or Oxaliplatin (OX) (biweekly schedule) was assessed in Asian populations with acceptable safety profile and efficacy...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have